PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds

MT Newswires Live

2025/09/12

PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.

NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.

The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566294468"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566294468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566294468?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566294468","market":"sh","top_or_hot":-1,"title":"PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds","media":"MT Newswires Live","content":"<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyNovo Requests Trading Halt Ahead of NovoSorb Device Trial Results in Neuroischemic Diabetic Wounds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-12 11:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.</p><p>NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.</p><p>The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566294468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566294468","pubTimestamp":1757646805,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PolyNovo  requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","PNV.AU":"POLYNOVO LTD","BK7508":"医药生物股"},"translate_title":"PolyNovo要求在NovoSorb设备试验结果导致糖尿病神经缺血性伤口之前暂停交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PNV.AU":0.9},"content_text":"PolyNovo (ASX:PNV) requested a trading halt for its securities on Friday in respect of a poster made public on the results of a chronic wound investigator-initiated clinical trial comparing the use of NovoSorb biodegradable temporizing matrix device combined with negative pressure wound therapy with the clinical standard-of-care in subjects with neuroischemic diabetic wounds, according to a same-day Australian bourse filing.NovoSorb is a synthetic, biodegradable device designed to facilitate the growth of skin tissue within a patented polyurethane matrix.The medical technology company requested the trading halt to remain in place until the release of an announcement or the opening of the market on Sept. 16.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}